- Home
- ADTX vs ISPC Comparison
ADTX vs ISPC Comparison
Compare ADTX & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADTX
- ISPC
- Stock Information
- Founded
- ADTX 2017
- ISPC 2009
- Country
- ADTX United States
- ISPC United States
- Employees
- ADTX N/A
- ISPC N/A
- Industry
- ADTX Biotechnology: Pharmaceutical Preparations
- ISPC Precision Instruments
- Sector
- ADTX Health Care
- ISPC Health Care
- Exchange
- ADTX Nasdaq
- ISPC Nasdaq
- Market Cap
- ADTX 5.3M
- ISPC 4.7M
- IPO Year
- ADTX 2020
- ISPC 2021
- Fundamental
- Price
- ADTX $0.13
- ISPC $2.37
- Analyst Decision
- ADTX
- ISPC
- Analyst Count
- ADTX 0
- ISPC 0
- Target Price
- ADTX N/A
- ISPC N/A
- AVG Volume (30 Days)
- ADTX 39.3M
- ISPC 1.2M
- Earning Date
- ADTX 11-18-2024
- ISPC 03-12-2025
- Dividend Yield
- ADTX N/A
- ISPC N/A
- EPS Growth
- ADTX N/A
- ISPC N/A
- EPS
- ADTX N/A
- ISPC N/A
- Revenue
- ADTX $212,107.00
- ISPC $10,390,702.00
- Revenue This Year
- ADTX $95.61
- ISPC $13.82
- Revenue Next Year
- ADTX $1,584.79
- ISPC $11.76
- P/E Ratio
- ADTX N/A
- ISPC N/A
- Revenue Growth
- ADTX N/A
- ISPC 0.74
- 52 Week Low
- ADTX $0.12
- ISPC $2.30
- 52 Week High
- ADTX $218.00
- ISPC $11.80
- Technical
- Relative Strength Index (RSI)
- ADTX 18.05
- ISPC 34.01
- Support Level
- ADTX $0.12
- ISPC $2.50
- Resistance Level
- ADTX $0.21
- ISPC $2.79
- Average True Range (ATR)
- ADTX 0.03
- ISPC 0.28
- MACD
- ADTX 0.03
- ISPC 0.02
- Stochastic Oscillator
- ADTX 9.91
- ISPC 6.48
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.